PDCD1 and hypophysitis: Furthermore, when both therapies are combined, hypophysitis is reported to occur at approximately twice the frequency of anti-CTLA-4 antibody monotherapy [4]. This case involved combined therapy with anti-PD-1 antibodies and anti-CTLA-4 antibodies, carrying a high risk of hypophysitis.